FDA approves 4-year intrauterine device
Allergan (NYSE:AGN) and women’s health nonprofit Medicines360 said today that the FDA approved a supplemental new drug application to extend the duration of use for Liletta, a levonorgestrel-releasing intrauterine device, for up to four years.
The hormone-releasing device was first approved in February 2015 and it won additional approval in January last year for a single-handed inserter.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA approves 4-year intrauterine device appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Allergan Inc. Medicines360 Source Type: news